Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 17/20 | 0.80 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.80 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.80 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.67 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.63 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.59 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL379076 | 0.93 | FFAR1 (0.73) | FFAR1FFAR4AKR1B1NR4A2MRGPRX4 | |
| SCHEMBL2772855 | 0.90 | FFAR1 (0.83) | FFAR1FFAR4AKR1B1NR4A2 | |
| SCHEMBL18165304 | 0.89 | FFAR1 (0.85) | FFAR1FFAR4AKR1B1PTGER4PTGER3 | |
| SCHEMBL1747107 | 0.89 | FFAR1 (1.00) | FFAR1FFAR4AKR1B1 | |
| SCHEMBL18165300 | 0.88 | FFAR1 (0.67) | FFAR1FFAR4AKR1B1NR4A2MRGPRX4 | |
| SCHEMBL8339114 | 0.88 | FFAR1 (0.78) | FFAR1FFAR4AKR1B1MRGPRX4PTGER4 | |
| SCHEMBL17413808 | 0.86 | FFAR1 (0.82) | FFAR1FFAR4 | |
| SCHEMBL7347912 | 0.85 | FFAR1 (0.69) | FFAR1FFAR4AKR1B1PTGER4PTGER3 | |
| SCHEMBL29381971 | 0.85 | FFAR1 (0.69) | FFAR1FFAR4AKR1B1PTGER4PTGER3 | |
| SCHEMBL22540400 | 0.85 | FFAR1 (0.62) | FFAR1FFAR4AKR1B1NR4A2MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856278-B2 | Lysophosphatidylserine derivative | THE UNIVERSITY OF TOKYO (JP) | 2018-01-02 | — | — | US | disclosed |
| US-9856278-B2 | Lysophosphatidylserine derivative | THE UNIVERSITY OF TOKYO (JP) | 2018-01-02 | — | — | US | disclosed |
| US-20170210767-A1 | LYSOPHOSPHATIDYLSERINE DERIVATIVE | THE UNIVERSITY OF TOKYO (JP) | 2017-07-27 | — | — | US | disclosed |
| US-20170210767-A1 | LYSOPHOSPHATIDYLSERINE DERIVATIVE | THE UNIVERSITY OF TOKYO (JP) | 2017-07-27 | — | — | US | disclosed |
| US-20170210767-A1 | LYSOPHOSPHATIDYLSERINE DERIVATIVE | THE UNIVERSITY OF TOKYO (JP) | 2017-07-27 | — | — | US | disclosed |
| WO-2016002948-A1 | LYSOPHOSPHATIDYLSERINE DERIVATIVE | 国立大学法人東京大学 | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210767-A1 | LYSOPHOSPHATIDYLSERINE DERIVATIVE | LPAR3, LPAR1, LPAR4 | FFAR1 84/4885FFAR4 80/4885AKR1B1 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.